The Largest Antithrombotic Trials
ENGAGE AF-TIMI 48: ENGAGE AF-TIMI 48 is the largest (21,105 patients) and the longest (median follow-up duration of 2.8 years) trial to date for stroke prevention in atrial fibrillation1,2.
Hokusai-VTE: Hokusai VTE is the largest (8,292 patients) study to date of a non-vitamin K antagonist oral anticoagulant (NOAC) in venous thromboembolism (VTE) that studied patients with DVT and/or PE3,4.
TRITON TIMI 38: TRITON TIMI 38 (13,608 patients) is the largest trial to date evaluating a potent platelet inhibitor in ACS-PCI to prevent major cardiovascular events5.
- We know how essential it is for patients and healthcare professionals to have full confidence in our products. That’s why we evaluate new treatments to the highest ethical standards. Daiichi Sankyo products are only made available once they have been evaluated through robust and high quality clinical trials, including the largest in their respective fields.
- That means our products are compared against standards of care, among a broad range of patients, including those most at risk.
- We do this to reflect best clinical practice and assure healthcare professionals of the dosing, safety and efficacy when prescribing our products to their patients.